Cary Claiborne, CEO of Adial Pharmaceuticals (NASDAQ: ADIL), shares insights into Adial’s non-abstinence-based approach to treating Alcohol Use Disorder (#AUD). By leveraging genetic markers, the company is paving the way for personalized precision medicine in addiction therapy. With the recent milestone of the PK study completion, Adial Pharmaceuticals is advancing closer to a phase three trial as it aims to provide an alternative solution for this public health challenge. Learn more via PharmaShots: https://bit.ly/49OWLEg #AlcoholUseDisorder #PrecisionMedicine
Adial Pharmaceuticals (NASDAQ: ADIL)
Pharmaceutical Manufacturing
Charlottesville, Virginia 2,206 followers
Medicines for Addiction
About us
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.
- Website
-
https://www.adial.com/
External link for Adial Pharmaceuticals (NASDAQ: ADIL)
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Charlottesville, Virginia
- Type
- Public Company
- Founded
- 2010
- Specialties
- drug abuse, drug addiction, alcohol abuse, and alcohol addiction
Locations
-
Primary
Get directions
1108 Seminole Trail
Charlottesville, Virginia, US
Employees at Adial Pharmaceuticals (NASDAQ: ADIL)
Updates
-
Adial Pharmaceuticals (NASDAQ: ADIL) reposted this
CEO @ Boudicca DX | Precision Medicine Consulting | Regulatory Professional | Clinical Biomarker Development | Companion Diagnostics | IVD Product Development | Clinical Molecular Technologist (LDTs) | Scientific Advisor
Listen to hear more about a personalized medicine approach for alcohol use disorder under development by Adial Pharmaceuticals (NASDAQ: ADIL) It really highlights the power of biomarkers and CDx for drug development 🧬
Listen as Cary Claiborne, CEO of Adial Pharmaceuticals (NASDAQ: ADIL), discusses AD04, an ultra-low-dose formulation of ondansetron, and its potential for treating Alcohol Use Disorder (AUD). AD04’s precision medicine approach could include a genetic test to drive uptake, offering a personalized treatment option. For more about Adial, please visit: https://bit.ly/4fNwY1V #PrecisionMedicine #AUD #ClinicalTrials #GeneticTesting
-
Listen as Cary Claiborne, CEO of Adial Pharmaceuticals (NASDAQ: ADIL), discusses AD04, an ultra-low-dose formulation of ondansetron, and its potential for treating Alcohol Use Disorder (AUD). AD04’s precision medicine approach could include a genetic test to drive uptake, offering a personalized treatment option. For more about Adial, please visit: https://bit.ly/4fNwY1V #PrecisionMedicine #AUD #ClinicalTrials #GeneticTesting
-
Adial Pharmaceuticals (NASDAQ: ADIL) has been granted a patent by USPTO, expanding the genotype combinations covered by our genetic diagnostic for the targeted treatment of Alcohol Use Disorder (#AUD) with AD04. This patent helps bolster our progress toward commercialization and our future ability to support patients with targeted therapies. Learn more: https://bit.ly/3CVj9zv #Patent #AlcoholUseDisorder #PrecisionMedicine
-
-
Adial Pharmaceuticals’ Tony Goodman shares how genetic biomarkers are redefining the treatment of Alcohol Use Disorder (#AUD), hosted by Karen Jagoda on the Empowered Patient Podcast By combining AD04 with companion diagnostics, listen to how Adial is paving the way for personalized addiction treatment, improving patient outcomes, and advancing the future of precision medicine. Listen to the episode here: https://bit.ly/3CLwvOA Download the transcript here: https://bit.ly/4g8KT1T #HealthcareInnovation #AddictionTreatment #PrecisionMedicine #AlcoholUseDisorder
-
-
Couldn’t attend the 2024 ThinkEquity LLC Conference? Watch the full recording of Adial Pharmaceuticals (NASDAQ: ADIL) CEO Cary Claiborne’s presentation, where he discusses our pioneering work in addiction treatment through precision medicine. 📺 Watch now: https://lnkd.in/gN92j42m #InvestorConference #AddictionTreatment #PrecisionMedicine
-
-
A report by Inside Precision Medicine offers valuable insights into the genetics of Alcohol Use Disorder (AUD). A study at RTI International identified hundreds of genes in key brain regions linked to addiction. At Adial Pharmaceuticals (NASDAQ: ADIL), understanding the genetic underpinnings of AUD supports our commitment to advancing more precise, genetically targeted treatments. Read more here: https://lnkd.in/e-BXZ4Z5 #AUD #GeneticResearch #PrecisionMedicine
-
-
Adial Pharmaceuticals (NASDAQ: ADIL) announces positive topline results from the AD04-103 pharmacokinetics (PK) study for AD04, our investigational treatment for Alcohol Use Disorder (#AUD). The study confirmed the relative bioavailability of AD04 to the reference standard, showed dose-proportional increases in PK exposure, and demonstrated no food effect. The PK study findings also further confirm the safety and tolerability of AD04. This milestone supports our Phase 3 design and upcoming FDA discussions. For more: https://bit.ly/3CvGbN1 #AlcoholUseDisorder #ClinicalTrials
-
-
Adial Pharmaceuticals (NASDAQ: ADIL) reports third quarter 2024 financial results and provides a business update. More here: https://bit.ly/3ADahxA
-
-
Adial Pharmaceuticals (NASDAQ: ADIL) welcomes Vinay Shah as our new Chief Financial Officer. With over 25 years of experience in finance within the pharmaceutical and healthcare sectors, Vinay brings expertise in financial strategy, investor relations, and operational efficiency. For more: https://lnkd.in/e6G96mtv #InvestorRelations #FinanceFunction
-